GP-100 antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
GP-100 antigen
DrugBank Accession Number
DB14800
Background

GP-100 antigen is under investigation in clinical trial NCT00006385 (Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma).

Type
Biotech
Groups
Investigational
Synonyms
  • GP100 ANTIGEN

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
1NU720978F
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentMelanoma (Skin) Stage IV / Recurrent Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma1
3TerminatedTreatmentIntraocular Melanoma1
2CompletedTreatmentCancer, Cancer Nonmelanoma Skin / Malignant Melanoma of Skin1
2CompletedTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Ciliary Body and Choroid Melanoma, Small Size / Extraocular Extension Melanoma / Iris Melanoma / Melanoma Stage Iv / Metastatic Intraocular Melanoma / Mucosal Melanoma / Recurrent Intraocular Melanoma / Recurrent Melanoma / Stage IIC Melanoma / Stage IIIA Intraocular Melanoma / Stage IIIA Melanoma / Stage IIIB Intraocular Melanoma / Stage IIIB Melanoma / Stage IIIC Intraocular Melanoma / Stage IIIc Melanoma / Stage IV Intraocular Melanoma1
2CompletedTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Extraocular Extension Melanoma / Iris Melanoma / Melanoma Stage Iv / Stage IIB Melanoma / Stage IIC Melanoma / Stage IIIA Melanoma / Stage IIIB Melanoma / Stage IIIc Melanoma1
2CompletedTreatmentExtraocular Extension Melanoma / Recurrent Intraocular Melanoma1
2CompletedTreatmentIntraocular Melanoma / Malignant Melanoma of Skin3
2CompletedTreatmentMalignant Melanoma of Skin11
2CompletedTreatmentMelanoma Stage Iv / Recurrent Melanoma1
2CompletedTreatmentMelanoma Stage Iv / Recurrent Melanoma / Renal Cell Cancer, Recurrent / Stage IV Renal Cell Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 14:27 / Updated on June 12, 2020 16:53